Intercept Shares Skyrocket After Liver Drug Nails Mid-Stage Study

Intercept Shares Skyrocket After Liver Drug Nails Mid-Stage Study.

Jan 9, 2014 at 10:03AM

Those that invested in the Intercept Pharmaceuticals (NASDAQ:ICPT) IPO last year are likely dancing in the streets today.

The New York-based biotech's shares soared more than 230 percent—from a $72.39 Wednesday close to $239.02—in pre-market trading. Investors are clamoring into the stock after Intercept announced that it stopped a mid-stage clinical trial early because the drug showed such an obvious benefit for liver patients. The drug, obeticholic acid (OCA), is being developed for nonalcoholic steatohepatitis (NASH), a leading cause of cirrhosis and liver failure.

The Phase IIb clinical trial, sponsored by the National Institutes of Health, was halted after an independent data safety monitoring board looked at liver biopsy data of about half of the 283 patients in the study before and after treatment and found a "highly statistically significant improvement" in their condition. The positive news from the study, known as FLINT, shocked even Intercept executives.

"The unexpected early stopping of FLINT due to OCA meeting the primary endpoint with such high significance is a major milestone," said Intercept CEO Mark Pruzanski, in a statement.

Nonalcoholic steateohepatitis, or NASH, is a condition in which fat builds up in the liver, leading to chronic inflammation and scarring that can ultimately cause cirrhosis and liver failure. It's seen in people with diets high in fat and sugar. About 12 percent of the U.S. population has NASH, according to studies cited by Intercept.

Intercept's drug, meanwhile, targets what's known as a farnesoid X receptor, which is found in high concentration in the liver and intestine. Intercept is testing the drug in patients with other rare forms of chronic liver disease like primary biliary cirrhosis. Intercept owns most of the rights to the drug. Dainippon Sumitomo holds rights to Intercept's drug in Japan and China.

Intercept went public last year at $15 per share.

Top Stock Pick for 2014

There's a huge difference between a good stock, and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report: "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

This article originally appeared on Xconomy, along with:

The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.


Compare Brokers